Connect with us
  • tg

Stock Markets

Altimmune Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity during Oral Presentation at the American Diabetes Association’s 84th Scientific Sessions

letizo News

Published

on

GAITHERSBURG, Md., June 23, 2024 (GLOBE NEWSWIRE) — Altimmune, Inc.  (Nasdaq: NASDAQ:), a clinical-stage biopharmaceutical company, today presented data from the 48-week Phase 2 MOMENTUM clinical trial of pemvidutide, its GLP-1/glucagon dual receptor agonist candidate, in obesity, including the results of a recently completed body composition analysis, at the American Diabetes Association’s (ADA) 84th Scientific Sessions.

We’re pleased with the data presented at ADA that highlight the impressive lean mass preservation achieved with pemvidutide, with only 21.9% of weight loss attributable to lean mass, said Vipin K. Garg, Ph.D., President and Chief Executive Officer of Altimmune. The preservation of lean mass observed in this trial was better than reported historically with diet and exercise programs and greater than what has been publicly reported with other incretin weight loss drugs, where lean mass has accounted for as much as 40% of total weight loss. Preservation of lean mass, which is primarily muscle tissue, is believed to be important in maintaining healthy weight loss and physical function. We believe that the level of muscle preservation observed in the Phase 2 trial further adds to the differentiation of pemvidutide in the treatment of obesity.

The trial enrolled 391 subjects with obesity, or overweight with at least one co-morbidity and without diabetes. Subjects were randomized 1:1:1:1 to 1.2 mg, 1.8 mg, 2.4 mg pemvidutide or placebo administered weekly for 48 weeks in conjunction with diet and exercise. A subgroup of subjects was evaluated in a body composition analysis.

At Week 48, subjects receiving pemvidutide achieved mean weight losses of 10.3%, 11.2%, 15.6% and 2.2% at the 1.2 mg, 1.8 mg, and 2.4 mg doses and placebo, respectively, with a near-linear continued weight loss observed on the 2.4 mg dose at the end of treatment. The full MRI-based body composition analysis included 50 subjects who received pemvidutide and showed that subjects in the pemvidutide groups had an average lean mass loss of 21.9% with 78.1% of weight loss attributable to fat. In addition, pemvidutide resulted in robust reductions in serum lipids and improvements in blood pressure without imbalances in cardiac events, arrhythmias or clinically meaningful increases in heart rate.

Obesity is a multifactorial disease, and patients will need a variety of treatment options that fit their specific needs and comorbidities, said Louis Aronne, M.D., Director of the Comprehensive Weight Control Center, Division of Endocrinology, Diabetes & Metabolism at Weill Cornell Medicine and Scientific Advisor of Altimmune. These latest findings are particularly exciting given that pemvidutide has not only demonstrated significant weight loss but an impressive ability to preserve lean mass. With its favorable safety profile to-date and the potential to drive clinically meaningful improvements in other obesity-related conditions such as dyslipidemia and hypertension, pemvidutide could offer a highly promising, long-term treatment option for multiple segments of the obese patient population to safely and effectively manage body weight.

About Pemvidutide

Pemvidutide is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and MASH. Activation of the GLP-1 and glucagon receptors is believed to mimic the complementary effects of diet and exercise on weight loss, with GLP-1 suppressing appetite and glucagon increasing energy expenditure. Glucagon is also recognized as having direct effects on hepatic fat metabolism, which is believed to lead to rapid reductions in levels of liver fat and serum lipids. In clinical trials to date, once-weekly pemvidutide has demonstrated compelling weight loss, robust reductions in triglycerides, LDL cholesterol, liver fat content and blood pressure. The¯U.S.¯FDA has granted Fast Track designation to pemvidutide for the treatment of MASH. Pemvidutide recently completed the MOMENTUM Phase 2 obesity trial and is being studied in the ongoing IMPACT Phase 2b MASH trial.

About Altimmune

Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit  www.altimmune.com.

Forward-Looking Statement

Any statements made in this press release relating to future financial or business performance, conditions, plans, prospects, trends, or strategies and other financial and business matters, including without limitation, the timing of key milestones for our clinical assets, and the prospects for the utility of, regulatory approval, commercializing or selling any product or drug candidates, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, when or if used in this press release, the words may, could, should, anticipate, believe, estimate, expect, intend, plan, predict and similar expressions and their variants, as they relate to Altimmune, Inc. may identify forward-looking statements. The Company cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time. Important factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including risks relating to: delays in regulatory review, manufacturing and supply chain interruptions, access to clinical sites, enrollment, adverse effects on healthcare systems and disruption of the global economy;  the reliability of the results of studies relating to human safety and possible adverse effects resulting from the administration of the Company’s product candidates; the Company’s ability to manufacture clinical trial materials on the timelines anticipated; and the success of future product advancements, including the success of future clinical trials. Further information on the factors and risks that could affect the Company’s business, financial conditions and results of operations are contained in the Company’s filings with the U.S. Securities and Exchange Commission, including under the heading Risk Factors in the Company’s most recent annual report on Form 10-K and our other filings with the SEC, which are available at www.sec.gov.

Follow @Altimmune, Inc. on  LinkedIn
Follow @AltimmuneInc on  Twitter

Company Contact:
Richard Eisenstadt
Chief Financial Officer
Phone: 240-654-1450
ir@altimmune.com

Investor Contacts:
Lee Roth
Burns McClellan
Phone: 646-382-3403
lroth@burnsmc.com

Julia Weilman
Burns McClellan
Phone: 646-732-4443
jweilman@burnsmc.com

Media Contact:
Danielle Cantey
Inizio Evoke, Biotech
Phone: 619-826-4657
Danielle.cantey@inizioevoke.com

Source: Altimmune, Inc

Stock Markets

Hamas says it has not left ceasefire talks after Israeli attacks

letizo News

Published

on

By Nidal al-Mughrabi and Maayan Lubell

CAIRO/JERUSALEM (Reuters) -A senior Hamas official said on Sunday that the Islamist group has not withdrawn from ceasefire talks with Israel after this weekend’s deadly attacks in Gaza that Israel said had targeted the group’s military leader Mohammed Deif.

But Izzat El-Reshiq, a member of the political office of Hamas, accused Israel of trying to derail efforts by Arab mediators and the United States to reach a ceasefire deal by stepping up its attacks in the enclave.

Saturday’s strike in the Khan Younis area of Gaza, in which at least 90 Palestinians were killed, according to local health authorities, has put the ceasefire talks in doubt.

There had been increasingly hopeful signs in recent days that a deal could be reached to halt fighting and return hostages held in Gaza.

Two Egyptian security sources at ceasefire talks in Doha and Cairo said on Saturday that negotiations had been halted after three days of intense talks.

Israeli Prime Minister Benjamin Netanyahu was expected to convene his close circle of ministers later on Sunday to discuss the talks.

The strike on Saturday which targeted Deif killed Rafa Salama, commander of Hamas’ Khan Younis brigade, the Israeli military said on Sunday, but there was no confirmation about the fate of Deif.

“The strike in Khan Younis was a result of surgical intelligence,” the head of the Shin Bet domestic security service said in a video released by the service from Rafah. He said 25 Hamas operatives who took part in the deadly Oct. 7 attack in southern Israel that triggered the war had been killed in the past week.

On Saturday, a senior Hamas official denied that Deif had been killed and the group said Israeli claims were aimed at justifying the attack.

Israel’s military chief said on Sunday in a televised statement that Hamas was concealing the truth about Deif’s fate, but stopped short of confirming whether he was alive or dead.

Israeli forces pressed ahead on Sunday with aerial and ground shelling of several areas across the Gaza Strip, home to 2.3 million people, most of whom have been displaced by the war.

A strike on a UN-run school in Nuseirat camp, one of Gaza’s eight longstanding refugee camps, killed 15 Palestinians and wounded dozens more, Hamas media and health officials said.

The Israeli military said the site was used as a base for Hamas fighters to attack Israeli forces and said numerous steps were taken to limit the risk of harming civilians, including the use of precise munitions and intelligence.

Residents said two missiles targeted the upper floor of the school, not far from the camp’s local market, usually busy with shoppers, where displaced families have also taken shelter nearby.

Earlier on Sunday, Israeli airstrikes on four houses in Gaza City killed at least 16 Palestinians and wounded dozens of others, medics said.

The Gaza health ministry said at least 38,584 Palestinians have been killed and 88,881 others injured in Israel’s military offensive since Oct. 7.

It added that 141 Palestinians were killed by Israeli military strikes across the Gaza Strip in the past day, the biggest one-day death toll in many weeks.

Gaza’s health ministry does not distinguish between combatants and non-combatants but officials say most of the dead throughout the war have been civilians.

© Reuters. FILE PHOTO: Palestinians gather near damage, following what Palestinians say was an Israeli strike at a tent camp in Al-Mawasi area, amid Israel-Hamas conflict, in Khan Younis in the southern Gaza Strip July 13, 2024. REUTERS/Mohammed Salem/File Photo

Israel says it has lost 326 soldiers in Gaza and says at least a third of the Palestinian fatalities are fighters.

The war began after a Hamas-led attack inside Israel on Oct. 7, that killed 1,200 people, mostly civilians, and saw around 250 taken hostage to Gaza, according to Israeli authorities.

Continue Reading

Stock Markets

Trump rally shooting victim died shielding family from bullets

letizo News

Published

on

(Reuters) -The person shot and killed at former President Donald Trump’s rally in Pennsylvania on Saturday was a 50-year-old volunteer firefighter who shielded his family to protect them as gunshots rang out, the state’s Governor Josh Shapiro said on Sunday.

The victim was identified as Corey Comperatore, according to his family’s posting on Facebook (NASDAQ:).

“The PA Trump Rally claimed the life of my brother, Corey Comperatore. The hatred for one man took the life of the one man we loved the most,” the victim’s sister said in the post on Sunday.

Comperatore previously served as the chief of the Buffalo Township Volunteer Fire Department, according to a report by the Pittsburgh Post-Gazette.

Shapiro said he had spoken to Comperatore’s family and he relayed parts of the conversation to reporters.

“Corey died a hero. Corey dove on his family to protect them last night at this rally,” Shapiro said. “Corey was the very best of us.”

Comperatore was survived by a wife and two daughters. “Corey was a girl dad,” Shapiro said.

Shapiro added: “Corey was a firefighter. Corey went to church every Sunday. Corey loved his community and most especially Corey loves his family.”

Shapiro described the victim “as an avid supporter of the former president.”

© Reuters. A satellite image around Republican presidential candidate and former U.S. President Donald Trump's rally location in Butler, Pennsylvania, U.S.  June 2, 2023.  Maxar Technologies/Handout via REUTERS

Trump had just begun his speech at the Pennsylvania rally when the sound of shots rang out and it became apparent that Trump was also injured when a bullet grazed his right ear.

The FBI has identified 20-year-old Thomas Matthew Crooks of Bethel Park, Pennsylvania, as the suspect in what the government is calling an assassination attempt on Trump.

Continue Reading

Stock Markets

Google parent close to $23 billion deal to buy cybersecurity startup Wiz, WSJ reports

letizo News

Published

on

(Reuters) – Google parent Alphabet (NASDAQ:) is in advanced talks to acquire cybersecurity startup Wiz for roughly $23 billion, the Wall Street Journal reported on Sunday, citing people familiar with the matter.

A deal could come together soon, assuming the talks don’t fall apart, the report added.

© Reuters. FILE PHOTO: Small figurines are seen in front of displayed Alphabet logo in this illustration taken February 11, 2022. REUTERS/Dado Ruvic/Ilustration/File Photo

Google and Wiz did not immediately respond to a Reuters’ request for comment.

The U.S.-Israeli startup raised $1 billion in a private funding round in May, which values the four-year-old cloud cybersecurity company at $12 billion.

Continue Reading

Trending

©2021-2024 Letizo All Rights Reserved